Saving the Lives of People with Blood Cancer
by
In this blog, our Science Communications Manager, Jonathan Kay, looks at how make-up products could cause infections post-transplant and the steps you can take to help reduce the risk. Picking up an infection is an understandable and realistic concern for all stem cell transplant patients because it can take some time for their donor’s stem…
by
In this blog, our Patient Information Writer and Researcher, Jonathan Kay, takes a closer look at the latest developments in and potential benefits of allo CAR T-cell therapy. Chimeric Antigen Receptor (CAR) T-cell therapy is an exciting new treatment that has recently been approved for children with B-cell acute lymphoblastic leukaemia (ALL), and adults with…
by
The annual EBMT conference was held in Frankfurt this year, and brought together the world’s leading stem cell transplantation clinicians and scientists to share their latest findings. Members of our Patient Services team attended the conference, alongside our clinical nurse specialists and our recently appointed clinical psychologists. These are their highlights. All aspects of stem…
by
After new findings from Anthony Nolan’s Patient/Donor project have been published, Jonathan from our Patient Services team looks at how new technology is helping us understand what the best possible match now looks like, and what this means for future patients. At Anthony Nolan, we use our stem cell register of over 700,000 people to…
by
Jonathan in our patient services team discusses emerging treatments for cancer, using cell therapy and new ‘super cells’. When developing a new cancer treatment, one of the most important things to consider is how well it can be tolerated by patients. Often the amount of drug that can be given is limited by the side…
by
Jonathan in the Patient Services team discusses recent research into the use of cell therapies to treat Graft versus Host Disease (GvHD), which is a common side effect of stem cell transplant. He also looks at the implications this may have for patients whose symptoms have not responded to standard treatments. Graft vs Host…
